Ironwood Pharmaceuticals (IRWD) Net Cash Flow (2010 - 2026)

Ironwood Pharmaceuticals (IRWD) has 17 years of Net Cash Flow data on file, last reported at $5.1 million in Q1 2026.

• For the quarter ending Q1 2026, Net Cash Flow fell 74.3% year-over-year to $5.1 million; the trailing twelve-month figure through Mar 2026 stood at $112.4 million (up 965.02% YoY), and the FY2025 full-year result was $127.2 million, up 3670.75% from the prior year.
• Net Cash Flow eased to $5.1 million in Q1 2026, from $74.7 million in the prior quarter.
• In the past five years, Net Cash Flow ranged from a high of $84.1 million in Q1 2023 to a low of -$565.5 million in Q2 2023.
• A 5-year average of -$23.6 million and a median of $327000.0 in 2024 frame the typical range for Net Cash Flow.
• Across the five-year window, Net Cash Flow sank 535.3% in 2023 and surged 22743.43% in 2025, its largest moves.
• Tracing IRWD's Net Cash Flow over 5 years: stood at $82.0 million in 2022, then plunged by 123.48% to -$19.3 million in 2023, then jumped by 101.7% to $327000.0 in 2024, then surged by 22743.43% to $74.7 million in 2025, then slumped by 93.14% to $5.1 million in 2026.
• Business Quant data shows IRWD's Net Cash Flow at $5.1 million in Q1 2026, $74.7 million in Q4 2025, and $47.6 million in Q3 2025.